Base Editing of TIGIT Reprograms CD155 Signaling in Natural Killer Cells to Enhance Cancer Immunotherapy Efficacy.

This laboratory study explored a new genetic editing technique to enhance natural killer (NK) cells, which are immune cells that naturally fight cancer. Researchers used "base editing" technology to modify a gene called TIGIT in human NK cells, achieving over 90% editing efficiency. This modification essentially flipped a switch, converting an inhibitory signal that normally suppresses NK cell activity into an activating signal that amplifies their cancer-fighting ability. The edited NK cells demonstrated enhanced ability to target and destroy cancer cells across multiple tumor types in laboratory tests. Importantly, the modified cells showed minimal unwanted genetic changes, suggesting safety, and could be frozen and thawed while maintaining their effectiveness, potentially making them suitable as an "off-the-shelf" therapy. When combined with IL-2, a immune-stimulating protein, the results were even more promising. This research represents an advancement in cellular immunotherapy for cancer treatment. However, this study does not involve acupuncture or traditional Chinese medicine. For patients currently undergoing cancer treatment, acupuncture may serve as a supportive therapy to help manage treatment-related side effects such as nausea, pain, and fatigue. If you are interested in incorporating acupuncture into your cancer care plan, consult with your oncology team and seek treatment from a licensed acupuncturist experienced in working with cancer patients.

This preclinical study demonstrates successful application of base-editing technology to modify the TIGIT gene in primary human peripheral blood-derived NK cells, achieving >90% editing efficiency. The genetic modification converted CD155-mediated inhibitory signaling through TIGIT into activating signaling via CD226, significantly enhancing NK cell cytotoxicity against multiple tumor types. TIGIT base-edited NK (TIGIT BE-NK) cells exhibited minimal off-target effects and maintained antitumor activity post-cryopreservation, supporting feasibility as an allogeneic cellular therapy. Combination with IL-2 further augmented therapeutic efficacy. This study is not directly relevant to acupuncture practice but represents important developments in cancer immunotherapy. Acupuncture practitioners working with oncology patients should remain informed about emerging cancer treatments to provide appropriate integrative care, particularly for managing immunotherapy-related side effects and supporting overall patient wellness during advanced cancer treatments.